Reduction of tariffs on patented pharmaceuticals and pharmaceutical ingredients for products of the United Kingdom
Tariffs on UK patented pharmaceuticals and pharmaceutical ingredients are reduced, easing import costs and shifting trade flows.
Source →The trace
How it reaches your house.
Starting from Hikma Pharmaceuticals, we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
Macfarlan Smith Ltd. (Esteve Pharmaceuticals) →Prices easeReduced UK tariff treatment should lower landed cost for Macfarlan Smith’s buprenorphine API exports, putting downward pressure on import prices in the destination market; the effect is material given the 20% market share and low substitutability.
81% confidenceMacfarlan Smith Ltd. (Esteve Pharmaceuticals) →Prices easeThebaine & oripavine (opium alkaloid precursors)
Tariff relief on UK pharmaceutical ingredients should reduce the import cost of Macfarlan Smith’s thebaine/oripavine precursors, though the transmission is smaller given the 8% share and higher replaceability.
74% confidenceHop 2
Buprenorphine API →
Where it lands
What you buy, and what you own.
Goods you buy
Controlled pain medicines (Rx)
Companies you may own
Macfarlan Smith Ltd. (Esteve Pharmaceuticals)
Tap a company to see what it told the SEC could break it.
In the MyPRIA app, this is checked against your own holdings.